Cardiomyocyte p65 nuclear factor-κB is necessary for compensatory adaptation to pressure overload

Hadi Javan1, Amanda M Szucsik1, Ling Li1

  • 1From the Division of Cardiothoracic Surgery, Department of Surgery and Molecular Medicine (H.J., A.M.S., L.L., C.L.S., C.H.S.) and Department of Pathology, ARUP Institute for Research and Development (M.E.S.), University of Utah, Salt Lake City.

Insights

Nuclear factor κB (NF-κB) plays a crucial role in heart adaptation to stress. Impaired NF-κB in heart cells worsens cardiac hypertrophy and accelerates heart failure by disrupting blood vessel growth and response to low oxygen.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Cardiac Pathophysiology

Background:

  • Nuclear factor κB (NF-κB) is recognized for its role in inflammation and immunity.
  • Its function in cardiac injury response is complex, with potential detrimental and beneficial roles.
  • Previous studies indicated that inhibiting NF-κB exacerbates pressure overload-induced heart failure.

Purpose of the Study:

  • To investigate the role of cardiomyocyte NF-κB in the adaptive response to pressure overload.
  • To determine if impaired angiogenesis mediated by NF-κB is a trigger for pathological left ventricular hypertrophy.
  • To elucidate the mechanistic link between NF-κB, hypoxia, and the transition to heart failure.

Main Methods:

  • Generated transgenic mice with cardiomyocyte-specific deletion of the p65 subunit of NF-κB.
  • Utilized transverse aortic constriction to induce pressure overload.
  • Assessed cardiac function, hypertrophy, fibrosis, and angiogenesis via echocardiography, histology, and molecular markers over 6 weeks.

Main Results:

  • Cardiomyocyte-specific NF-κB deletion accelerated maladaptive left ventricular hypertrophy and heart failure progression.
  • NF-κB deficient mice exhibited increased cardiac fibrosis and periostin expression.
  • Despite increased capillary domain areas, microvessel density and hypoxia-inducible factor 1α expression were decreased.

Conclusions:

  • Loss of cardiomyocyte NF-κB impairs compensatory hypertrophy, leading to functional deterioration under pressure overload.
  • NF-κB deficiency promotes cardiac fibrosis and hinders the response to hypoxic stress.
  • These findings mechanistically link NF-κB-regulated hypoxic response to the maladaptive progression from cardiac hypertrophy to heart failure.
Abstract

Related Concept Videos

Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy:...
5
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.6K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
811
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
812
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.9K